Shares of Eli Lilly (LLY) are up $11.11, or about 2%, to $709.29 in pre-market trading while those of Novo Nordisk (NVO) trading in New York are also up 2% to $54.83 after potential weight loss drug competitor Viking Therapeutics (VKTX) announced top-line results from the company’s Phase 2 clinical trial of the oral tablet formulation of VK2735.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Analysts Rally Behind Eli Lilly (LLY) Stock After 24% Slide
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories
- Eli Lilly (LLY) Signs $1.3 Billion Deal with Superluminal to Discover Future Drugs Using AI
- Novo Nordisk (NVO) Stock Gains as Wegovy Drug Gets FDA Nod for Liver Disease
- Eli Lilly downgraded to Neutral from Outperform at Daiwa